CTRI/2019/10/021632招募中2 期
A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Individualized Homeopathic Medicines in Irritable Bowel Syndrome using Homeopathic Repertory
Mahesh Bhattacharyya Homoeopathic Medical College Hospital Govt of West Bengal0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a) Patients suffering from IBS
- •b) Both sexes
- •c) Age 18-65 years
- •d) Literate patients with ability to read Bengali and/or English
- •e) Patients willing to participate in the study and giving written informed consent.
排除标准
- •a) Patients who are too unwell to take part
- •b) Inability to read patient information sheets and/or denied consent to take part
- •c) Diagnosed cases of unstable psychiatric complaints or other systemic diseases affecting quality of life
- •d) Any major gastro-intestinal surgery in last 6 months
- •e) Currently receiving standard therapy for IBS and/or homoeopathic treatment for any chronic condition(s)
- •f) Pregnant and lactating women
- •g) Self-reported immune compromised conditions
- •h) Substance abuse and/or dependence
研究者
相似试验
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-FRMarinus Pharmaceuticals, Inc.70
已完成
2 期
Homeopathic medicines for eczemaCTRI/2019/10/021712Mahesh Bhattacharyya Homoeopathic Medical College Hospital Govt of West Bengal60
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-GBMarinus Pharmaceuticals, Inc.100
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-ITMarinus Pharmaceuticals, Inc.70
进行中（未招募）
1 期
A trial for children and teenagers with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) to determine how effective Ganaxolone treatment is.EUCTR2018-001180-23-PLMarinus Pharmaceuticals, Inc.100